151 related articles for article (PubMed ID: 9724378)
1. Somatostatin receptor imaging in patients with sarcoidosis.
Kwekkeboom DJ; Krenning EP; Kho GS; Breeman WA; Van Hagen PM
Eur J Nucl Med; 1998 Sep; 25(9):1284-92. PubMed ID: 9724378
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy.
Nocaudie M; Bailliez A; Itti E; Bauters C; Wemeau JL; Marchandise X
Eur J Nucl Med; 1999 May; 26(5):511-7. PubMed ID: 10382096
[TBL] [Abstract][Full Text] [Related]
3. The visualization of granulomatous disease with somatostatin receptor scintigraphy.
Oztürk E; Günalp B; Ozgüven M; Ozkan S; Sipit T; Narin Y; Bayhan H
Clin Nucl Med; 1994 Feb; 19(2):129-32. PubMed ID: 7910542
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
5. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.
Breeman WA; Kwekkeboom DJ; Kooij PP; Bakker WH; Hofland LJ; Visser TJ; Ensing GJ; Lamberts SW; Krenning EP
J Nucl Med; 1995 Apr; 36(4):623-7. PubMed ID: 7699456
[TBL] [Abstract][Full Text] [Related]
6. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogue scintigraphy in granulomatous diseases.
Vanhagen PM; Krenning EP; Reubi JC; Kwekkeboom DJ; Bakker WH; Mulder AH; Laissue I; Hoogstede HC; Lamberts SW
Eur J Nucl Med; 1994 Jun; 21(6):497-502. PubMed ID: 8082663
[TBL] [Abstract][Full Text] [Related]
8. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
[TBL] [Abstract][Full Text] [Related]
9. Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats.
Breeman WA; de Jong M; Bernard BF; Bakker WH; Rolleman EJ; Kwekkeboom DJ; Visser TJ; Krenning EP
Nucl Med Biol; 1997 Nov; 24(8):749-53. PubMed ID: 9428601
[TBL] [Abstract][Full Text] [Related]
10. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
11. Dynamic indium-111-pentetreotide scintigraphy in breast cancer.
Bajc M; Ingvar C; Palmer J
J Nucl Med; 1996 Apr; 37(4):622-6. PubMed ID: 8691252
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor scintigraphy and gallium scintigraphy in patients with sarcoidosis.
Lebtahi R; Crestani B; Belmatoug N; Daou D; Genin R; Dombret MC; Palazzo E; Faraggi M; Aubier M; Le Guludec D
J Nucl Med; 2001 Jan; 42(1):21-6. PubMed ID: 11197973
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide.
McCart JA; Mehta N; Scollard D; Reilly RM; Carrasquillo JA; Tang N; Deng H; Miller M; Xu H; Libutti SK; Alexander HR; Bartlett DL
Mol Ther; 2004 Sep; 10(3):553-61. PubMed ID: 15336655
[TBL] [Abstract][Full Text] [Related]
14. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
15. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
16. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor scintigraphy using [111In-DTPA0]RC-160 in humans: a comparison with [111In-DTPA0]octreotide.
Breeman WA; van Hagen PM; Kwekkeboom DJ; Visser TJ; Krenning EP
Eur J Nucl Med; 1998 Feb; 25(2):182-6. PubMed ID: 9473268
[TBL] [Abstract][Full Text] [Related]
18. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
19. Indium-111-pentetreotide in Graves' disease.
Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
[TBL] [Abstract][Full Text] [Related]
20. Indium-111-pentetreotide scintigraphy in Graves' ophthalmopathy.
Kahaly G; Diaz M; Hahn K; Beyer J; Bockisch A
J Nucl Med; 1995 Apr; 36(4):550-4. PubMed ID: 7699440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
